Hoth Therapeutics Files 8-K
Ticker: HOTH · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1711786
| Field | Detail |
|---|---|
| Company | Hoth Therapeutics, Inc. (HOTH) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: HOTH
TL;DR
HOTH filed an 8-K on Jan 24 for Jan 23 events, mostly other events and financials.
AI Summary
Hoth Therapeutics, Inc. filed an 8-K on January 24, 2025, reporting on events that occurred on January 23, 2025. The filing primarily concerns other events and includes financial statements and exhibits. The company is incorporated in Nevada and its principal executive offices are located in New York.
Why It Matters
This 8-K filing indicates that Hoth Therapeutics, Inc. is providing updates on its corporate activities and financial reporting to the SEC.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on corporate events and financial statements, not indicating any immediate significant operational or financial distress.
Key Players & Entities
- Hoth Therapeutics, Inc. (company) — Registrant
- January 23, 2025 (date) — Date of earliest event reported
- January 24, 2025 (date) — Date of Report
- Nevada (jurisdiction) — State of incorporation
- New York (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Hoth Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and to include 'Financial Statements and Exhibits' as of January 23, 2025.
When was this 8-K report filed with the SEC?
This 8-K report was filed on January 24, 2025.
In which state is Hoth Therapeutics, Inc. incorporated?
Hoth Therapeutics, Inc. is incorporated in Nevada.
What is the address of Hoth Therapeutics, Inc.'s principal executive offices?
The address of Hoth Therapeutics, Inc.'s principal executive offices is 1177 Avenue of the Americas, 5th Floor, Suite 5066, New York, NY 10036.
What is the telephone number for Hoth Therapeutics, Inc.?
The telephone number for Hoth Therapeutics, Inc. is (646) 756-2997.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-01-24 16:15:32
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value HOTH The Nasdaq Stock Mar
- $1.00 — ock had a closing bid price at or above $1.00 per share for a minimum of 10 consecuti
Filing Documents
- ea0228609-8k_hoth.htm (8-K) — 27KB
- ea022860901ex99-1_hoth.htm (EX-99.1) — 8KB
- 0001213900-25-006526.txt ( ) — 253KB
- hoth-20250123.xsd (EX-101.SCH) — 3KB
- hoth-20250123_def.xml (EX-101.DEF) — 26KB
- hoth-20250123_lab.xml (EX-101.LAB) — 35KB
- hoth-20250123_pre.xml (EX-101.PRE) — 24KB
- ea0228609-8k_hoth_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On January 23, 2025, Hoth Therapeutics, Inc. (the "Company") received a letter from The Nasdaq Stock Market, LLC ("Nasdaq") stating that because the Company's common stock had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). On January 24, 2025, the Company issued a press release announcing that it has regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial
Item 9.01 Financial (d) Exhibits. Exhibit No. Description 99.1 Press Release of Hoth Therapeutics, Inc. dated January 24, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 24, 2025 Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer 2